bisoprolol | Biol tablets 10 mg 50 pcs. pack

Release form

Film-coated tablets.

Packaging

50 pieces per pack.

Pharmacological action

Biol - selective beta1-blocker without its own sympathomimetic activity. It does not have a membrane stabilizing effect. Reduces the activity of renin in blood plasma, reduces the need for myocardium in oxygen, reduces heart rate at rest and during exercise. It has hypotensive, antiarrhythmic and antianginal effects. Blocking in low doses the 1-adrenergic receptors of the heart, it reduces the formation of cAMP stimulated by catecholamines from ATP, reduces the intracellular current of calcium ions, and has a negative chrono-, dromo-, batmo- and inotropic effect. It inhibits conduction and excitability, slows AV-conduction. OPSS in the first 24 hours of drug use increases (as a result of a reciprocal increase in the activity of -Adrenoreceptors and the elimination of stimulation of 2-adrenergic receptors), which returns to its original state after 1-3 days, and decreases with prolonged administration.

The antihypertensive effect is associated with a decrease in minute blood volume, sympathetic stimulation of peripheral vessels, a decrease in the activity of the renin-angiotensin system (more important for patients with initial hypersecretion of renin), restoration of the sensitivity of the aortic arch baroreceptors (there is no increase in their activity in response to a decrease in blood pressure and effects on the central nervous system). With arterial hypertension, the effect occurs after 2-5 days, a stable hypotensive effect after 1-2 months.

The antianginal effect is due to a decrease in myocardial oxygen demand as a result of decreased heart rate and reduced contractility, lengthening of diastole, and improved myocardial perfusion. By increasing the final diastolic pressure in the left ventricle and increasing the stretching of the muscle fibers of the ventricles, it can increase the need for oxygen, especially in patients with chronic heart failure.

Antiarrhythmic effect is due to the elimination of arrhythmogenic factors (tachycardia, increased activity of the sympathetic nervous system, increased content of cAMP, arterial hypertension), a decrease in the rate of spontaneous excitation of sinus and ectopic pacemakers, and a slowdown in AV conduction (mainly in antegrade and, to a lesser extent, in retrograde directions through the AV node) and along additional paths.

When used in medium therapeutic doses, unlike non-selective beta-blockers, it has a less pronounced effect on organs containing 2-adrenergic receptors (pancreas, skeletal muscle, smooth muscles of the peripheral arteries, bronchi and uterus) and on carbohydrate metabolism. Does not cause sodium ion retention in the body. With an increase in the dose above the therapeutic, it has a beta2-blocking effect.

Indications

Arterial hypertension.

ischemic heart disease (prevention of angina attacks).

Contraindications

severe arterial hypotension (systolic blood pressure less than 90 mmHg, especially with myocardial infarction)

acute heart failure with chronic heart disease, chronic blockade of II and III degree (without the installation of a pacemaker)

sinoatrial blockade

sinus weakness syndrome

severe sinus bradycardia (heart rate less than 50 beats / min)

ty elye stage of peripheral circulatory disorders, Raynaud's disease

concomitant use of MAO inhibitors (except for type B MAO)

metabolic acidosis

severe asthma and chronic obstructive pulmonary disease (history)

age 18 years (efficacy and safety not established)

pregnancy and lactation

increased sensitivity to bisoprolol and other components of the drug and to other beta-blockers.

Precautions: severe liver failure

severe renal failure

thyrotoxicosis

psoriasis

myasthenia gravis

AV block I degree

angina pectoris Prmetzmetala

depression (including history)

pheochromocytoma (simultaneous use of alpha-blockers is mandatory)

diabetes mellitus

general anesthesia / surgical intervention

severe allergic reactions (history).

Special instructions

Treatment with Biol should not be abruptly interrupted because of the risk of severe arrhythmias and myocardial infarction. Cancellation is carried out gradually, reducing the dose by 25% every 3-4 days.

Monitoring of patients taking Biol should include measurement of heart rate and blood pressure (at the beginning of treatment - daily, then 1 time every 3-4 months), ECG, determination of glucose level in patients with diabetes mellitus.

Composition of

1 tablet contains bisoprolol calcium phosphate, 10 mg calcium phosphate sodium, magnesium stearate, silicon dioxide colloidal anhydrous.

Dosage and administration of

Tablets should be taken in the morning, regardless of food intake, do not chew, drink with a small amount of

liquid. In all cases of arterial hypertension and angina pectoris, the doctor sets the dosage regimen individually, taking into account the heart rate and the patient's condition. The initial daily dose is 5 mg (sometimes 2.5 mg) 1 time per day, if necessary, increase the dose to 10 mg 1 time per day. The maximum daily dose is 20 mg.

In patients with severe renal failure (CC less than 20 ml / min) or with severe impaired liver function, the maximum daily dose should not exceed 10 mg.

Dose adjustments for elderly patients are usually not required, however, for some patients, a dose of 5 mg per day may be optimal.

Side effects of the

From the side of the central nervous system: increased fatigue, weakness, asthenia, dizziness, headache, sleep disturbances, nightmares, mental disorders (depression), paresthesia in the extremities (in patients with intermittent claudication and Raynaud's syndrome), impaired concentration , myasthenia gravis, tremor.

From the side of the organ of vision: visual impairment, decreased secretion of lacrimal fluid (should be taken into account when wearing contact lenses), dryness and soreness of the eyes, conjunctivitis.

From the cardiovascular system: orthostatic hypotension, pain in the sternum, sinus bradycardia, impaired myocardial conduction, AV block, withdrawal syndrome (increased angina attacks, increased blood pressure), manifestation of angiospasm (increased peripheral circulation disorders, coldness of the lower extremities, syndrome Raynaud), development (aggravation) of the course of chronic heart failure.

From the digestive system: dry oral mucosa, nausea, vomiting, dyspepsia, diarrhea, taste change, liver dysfunction (symptoms of cholestasis), hepatitis, increased levels of ALT, AST, bilirubin.

From the respiratory system: nasal congestion, pharyngitis, rhinitis, sinusitis, cough, in predisposed patients - laryngo- and bronchospasm.

From the skin: increased sweating, skin hyperemia, exanthema, psoriasis-like skin reactions, exacerbation of psoriasis symptoms, alopecia.

From the hemopoietic system: thrombocytopenia, agranulocytosis, leukopenia.

Allergic reactions: pruritus, rash, urticaria.

Other: increased sweating, back pain, arthralgia, muscle pain, impaired sexual function, dysuria, hyperglycemia (in patients with non-insulin-dependent diabetes mellitus), hypoglycemia (in patients receiving insulin), hypothyroid state, increased triglycerides.

Drug Interactions

Allergens used for immunotherapy (or allergen extracts for skin tests) increase the risk of severe systemic allergic reactions and anaphylaxis in patients receiving bisoprolol.

Cardiac glycosides, methyldopa, reserpine and guanfacine, slow calcium channel blockers (verapamil, diltiazem), amiodarone, and other antiarrhythmic drugs increase the risk of developing or exacerbating bradycardia, AV blockade, cardiac arrest, and heart failure.

Diuretics, clonidine, sympatholytics, hydralazine, nifedipine and other antihypertensive drugs can lead to an excessive decrease in blood pressure.

Iodine-containing radiopaque agents for iv administration increase the risk of anaphylactic reactions.

Phenytoin with iv administration, drugs for inhalation general anesthesia (hydrocarbon derivatives) increase the severity of cardiodepressive action and the likelihood of lowering blood pressure.

Bisoprolol masks the adrenergic symptoms of thyrotoxicosis and hypoglycemia (e.g., tachycardia).

Reduces clearance of lidocaine and xanthines (except diphillin) and increases their concentration in blood plasma, especially in patients with initially increased clearance of theophylline under the influence of smoking.

The antihypertensive effect of bisoprolol is weakened by NSAIDs (sodium ion retention and prostaglandin synthesis blockade by the kidneys), GCS and estrogens (sodium ion retention).

Extends the effect of non-depolarizing muscle relaxants and the anticoagulant effect of coumarins.

Tri- and tetracyclic antidepressants, antipsychotics (antipsychotics), ethanol, sedatives and hypnotics increase CNS depression.

The simultaneous use with MAO inhibitors is not recommended due to a significant increase in the antihypertensive effect, the break in treatment between taking MAO inhibitors and bisoprolol should be at least 14 days.

Non-hydrogenated ergot alkaloids increase the risk of peripheral circulation disorders.

Sulfasalazine increases the concentration of bisoprolol in blood plasma.

Rifampicin shortens T 1/2 of bisoprolol.

Overdose

Symptoms: arrhythmia, ventricular extrasystole, severe bradycardia, AV blockade, severe BP, acute heart failure, hypoglycemia, acrocyanosis, shortness of breath, bronchospasm.

Treatment: gastric lavage and the appointment of adsorbing drugs. Carry out symptomatic therapy: at the developed AV blockade - in / in introduction of atropine (1-2 mg), epinephrine or staging of a temporary pacemaker at ventricular extrasystole - lidocaine (IA class drugs are not applied) at reduction of BP - the patient should be in a position no signs of pulmonary edema - in / in plasma replacement solutions, with inefficiency - administration of epinephrine, dopamine, dobutamine (to maintain chronotropic and inotropic action) in heart failure - cardiac glycosides, diuretics ki, glucagon in convulsions - in / in diazepam in bronchospasm - beta 2-adrenomimetics inhalation.

Storage Conditions

Keep out of the reach and sight of children at temperatures not exceeding 25 РC.

active substance

bisoprolol

Terms leave through pharmacies

In retseptu

lekarstvennaja form

tablets

Indications

Indications

Hypertension, Heart failure, arrhythmia

S.I.F.I. S.p.A., Italy